Serum opsonic deficiency produced by Streptococcus pneumoniae and by capsular polysaccharide antigens. by Giebink, G. S. et al.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 51 (1978), 527-538
Serum Opsonic Deficiency Produced by Streptococcus
Pneumoniae and by Capsular Polysaccharide Antigens
G. SCOTT GIEBINK, JAMES V. GREBNER, YOUNGKI KIM,
AND PAUL G. QUIE
Department of Pediatrics, University of Minnesota School of Medicine,
Minneapolis, Minnesota
Received May 22, 1978
The opsonic requirements for phagocytosis of S. pneumoniae types 6, 7, 18, and 23 were determined in
normal and C2 deficient serum, and in normal serum chelated with magnesium ethyleneglycoltetraacetic
acid. All four strains were effectively opsonized via the alternative complement pathway, a finding
suggesting that the capsular polysaccharides of these strains activated complement via the alternative
pathway. Since bacteremic pneumococcal disease is often associated with circulating capsular polysacchar-
ide, it was considered that this cellular component may activate complement in vivo and impair host defenses
by producing an opsonic defect for pneumococci. To examine this hypothesis, serum was incubated with
suspensions of whole S. pneumoniae types 6, 7, 18, or 23 or with purified capsular polysaccharide from each
of these types, and residual complement activity and opsonic capacity were measured. Hemolytic C 3-9
complement activity and opsonic capacity for 3H-thymidine labeled Salmonella typhimurium, a species
effectively opsonized via the alternative pathway, were reduced in serum following incubation. Polysacchar-
ide concentrations as low as I,u g/ml inhibited serum opsonic capacity for salmonella. Whole pneumococci
and pneumococcal capsular polysaccharide also inhibited the opsonic activity of human C2 deficient serum
for salmonella, further evidence for activation of complement via the alternative pathway. Pneumococcal
capsular polysaccharide markedly inhibited the opsonic capacity of normal serum for the homologous
pneumococcal type. Thus, amounts of pneumococcal capsular polysaccharide, similar to those found in the
serum of patients with pneumococcal disease, bring about decomplementation of serum via activation ofthe
alternative pathway and inhibit pneumococcal opsonization.
Patients with bacteremic disease dueto Streptococcuspneumoniae frequently have
circulating pneumococcal capsular polysaccharide (PCP)* with serum antigen levels
as high as 50' g/ml, detectable antigenemia for as long as 30 days and depressed
serum levels of C3 [1,2,3,4]. Since pneumococcal opsonic activity in the non-immune
individual is primarily related to cleavage ofC3 and fixation ofopsonically active C3b
to the bacterial surface [5,6], it was considered that patients with pneumococcal
infection and antigenemia may have acquired a pneumococcal opsonic defect. In
addition, since many pneumococcal serotypes are opsonized by activation of C3 via
the alternative pathway [5,7,8,9,10], an antigen induced opsonic defect may interfere
with phagocytosis.
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All rights of reproduction in any form reserved.To test this hypothesis pooled normal human serum or C2 deficient human serum
was incubated with whole S. pneumoniae (Pn) types 6, 7, 18, or 23 or with purified
PCP from these types. Serum opsonic capacity was measured after incubation with
whole bacteria or PCP by a functional assay employing neutrophil phagocytosis of
methyl-3H-thymidine labeled Salmonella typhimurium. This species is effectively
opsonized via the alternative pathway, thereby permitting evaluation of opsonic
activity mediated by the alternative pathway [11]. Both whole pneumococci and PCP
of the types tested caused a reduction of serum opsonic capacity and depletion of
hemolytic C activity, although inhibition of opsonization varied among the
serotypes. Both whole pneumococci and PCP of two representative serotypes also
reduced the opsonic capacity of C2 deficient serum, evidence for activation of the
alternative pathway.
MATERIAL AND METHODS
Bacteria and PCP. S. pneumoniae types 18 and 23 were isolated from children
with bacteremia; type 6 was obtained from the American Type Culture Collection
(Rockville, MD); and type 7 was kindly provided by Dr. Robert Austrian (University
of Pennsylvania, Philadelphia, PA). Serotypes were confirmed with group-specific
antisera (Statens Seruminstitut, Copenhagen, Denmark), and encapsulation was
maintained by monthly mouse passage. Purified PCP of types 6A, 7F, 18C, and 23F
were kindly supplied by Dr. James Hill (Development and Applications Branch,
National Institute of Allergy and Infectious Disease, National Institutes of Health,
Bethesda, MD). These highly purified polysaccharides were in lyophilized form
without preservative and have been shown to contain less than 0.00 1 A g endotoxin by
both an in vivo rabbit assay and by the limulus lysate test; nitrogen content was less
than 3% and protein content was less than 1% of their dry weight (Dr. James Hill,
personal communication). They have been prepared in accordance with procedures
for the manufacture of pneumococcal vaccines by the Lilly Research Laboratories,
Indianapolis, Indiana. The strain of Salmonella typhimurium employed has been
used in our laboratory forseveral years.
Bacterial preparation and labeling. This procedure is described in detail elsewhere
[5]. Briefly, S. pneumoniae were grown in Mueller-Hinton broth (Difco, Detroit, MI)
enriched with 3% bovine albumin, and with 1% D-glucose added during the final two
hours of incubation at 37°C. A total of 0.05 mCi methyl-3H-thymidine (specific
activity 6.7 Ci/mM, New England Nuclear, Boston, MA) was added to 10 ml of the
growth medium. After overnight incubation at 370C, the bacteria were harvested by
centrifugation and washed three times with isotonic phosphate-buffered saline, pH
7.4 (PBS). Pneumococci were killed by heating at 65°C for 45 min, counted in a
Petroff-Hauser chamber, suspended in PBS to 2.5 x 108 bacteria/ml and stored at
4°C for no longer than 7 days. For experiments employing suspensions of whole,
viable S. pneumoniae, the bacteria were prepared by identical methods except they
were not heat-killed and were used on the day of preparation.
S. typhimurium was grown in Mueller-Hinton broth enriched with 0.1 mg/ ml 2'-
deoxyadenosine (Sigma, St. Louis, MO) and containing 0.04 mCi methyl-3H-
thymidine. The labeled bacteria were washed three times in PBS, suspended to 5 x
108/ml and used the same day.
Leukocytes. Leukocytes were separated from heparinized blood of healthy adults
by dextran sedimentation, washed and suspended in Hank's Balanced Salt Solution
(Grand Island Biological Co., Grand Island, NY) with 0.1% gelatin (gel-HBSS) at a
concentration of 1 x 107 neutrophils per ml.
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Opsonins. Sera from three healthy adult donors were pooled, divided into 1 ml
aliquots, and used throughout these experiments. Once thawed, unused serum was
discarded. Type-specific pneumococcal antibody was kindly determined by Dr.
Gerald Schiffman, Downstate Medical Center, Brooklyn, NY, using a sensitive
radioimmunoassay method with results expressed in ng of antibody nitrogen
(ngAbN) per ml [12]. The serum pool contained normal levels ofantibody to types 7,
18, and 23 (214, 668, and 363 ngAbN/ml, respectively) but a lower concentration of
type 6 antibody (92 ngAbN/ml). To study opsonization inthe absence ofthe classical
complement pathway, undiluted serum was chelated by the addition of 0.1 M
ethyleneglycoltetraacetic acid in the presence of 0.1 M MgCl2 (MgEGTA) to each 1
ml of serum for a final chelator concentration of 0.01 M [13]. Calcium and
magnesium-free gel-HBSS was used to dilute the chelated serum. In addition, serum
was obtained from a patient with inherited complete C2 deficiency. This serum
contained normal levels ofall other classical and alternative complement components
[14], and had a normal capacity for alternative pathway opsonization of Staphylo-
coccus epidermidis and of S. aureus, Wood 46 [15]. All sera were divided into
aliquots and stored at -70°C. Heat-inactivated serum was prepared by incubation at
56°C for 30 min.
Bacterial opsonization. Bacteria were opsonized by adding 0.4 ml of the desired
opsonin to a plastic tube (12 x 75 mm, Falcon, Oxnard, CA) containing 0.1 ml of
radiolabeled bacteria. After 30 min incubation at 370C, the mixture was centrifuged
at 1600 g for 15 min. The supernatant was discarded, and the bacterial pellet was
resuspended in 0.5 ml gel-HBSS.
Determination of phagocytosis. The phagocytosis mixtures consisted of the
opsonized bacterial suspension and 0.5 ml leukocytes suspended in gel-HBSS. The
bacteria:neutrophil ratio was 5:1 for experiments with labeled pneumococci and 20:1
for studies with salmonella. Immediately following addition of leukocytes, the
mixtures were aliquoted in 250 1I volumes to four polypropylene vials (Bio-vials,
Beckman, Chicago, IL) which were agitated in a shaking incubator (Model 25, New
Brunswick Scientific, New Brunswick, NJ) at 37°C. After 30 min incubation, 2 ml
cold PBS was added to each of two vials to arrest phagocytosis. To determine
neutrophil-associated bacteria, vials were centrifuged for 5 min at 160 g at 40C, the
pellets were washed twice in 2 ml cold PBS and were resuspended in 2.5 ml
scintillation liquid (toluene with 20% Bio-Solve-3 in Fluoralloy, Beckman). The total
bacterial population in the phagocytosis mixture was determined by adding 2 ml cold
distilled water to each of the two remaining vials, centrifuging at 1600 g for 15 min
and resuspending the pellet in 2.5 ml scintillation liquid. The samples were counted in
a liquid beta scintillation counter (Beckman, LS-250). Chemical quenching was
similar for all samples. Duplicate values were within 5% of agreement, and an
average of the duplicate values was used in all calculations.
Bacterial uptake by the PMN leukocytes (% phagocytosis) at a given samplingtime
was calculated according to the formula:
% phagocytosis = cpm in 160 g pellet 1
cpm in 1600 g pellet
The cpm in the denominator was always at least 50 times greater than background
radioactivity.
Pneumococcal and salmonella opsonic requirements were defined using dilutions
of normal pooled serum (NPS), MgEGTA chelated NPS, C2 deficient serum and
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for 30 min, and results were expressed as percent bacterial phagocytosisfollowing an
additional 30 min incubation of opsonized bacteria with leukocytes. Each value was
the mean of at least four experiments, except when C2 deficient serum was used and
duplicate studies were performed. Differences were calculated by student's t-test for
unpaired observations.
The effect of Pn and PCP on serum opsonic activity was studied bypreincubating
serum with Pn, PCP, and with an equal volume of saline. Residual opsonic activity,
which was reflected by the percent bacterial phagocytosis, was expressed as the
percentage of the saline control. Normal serum was diluted to 2.5% and C2 deficient
serum was diluted to 5% for the salmonella opsonic assay. Serum was diluted to l1o0
for the pneumococcal opsonic assay. Each value was the mean of at least four
experiments unless otherwise indicated. The significance of opsonic inhibition was
calculated using the difference in percent phagocytosis between serum preincubated
with saline and Pn or PCP. Student's t-test for paired observations was employed.
Experiments with 5 and 1p&g/ml ofPCP were performed once and were not analyzed
for significance.
Hemolytic C3.9 titration. The assay for hemolytic C3.9activity was carried out as
previously reported [16,17]. Test samples were serially diluted in EDTA buffer. To
1.0 ml of each dilution of test sample was added 1.0 ml of EDTA buffer. EACI
(guinea pig) 4 (human) 2 (guinea pig) was prepared at T-max, and 1.0 ml ofEAC142
(5 x 107/ml) was added to each tube. After 60 minincubation at 37°C, 4.5 ml ofcold
normal saline was added, and the tubes were centrifuged. The optical density (412
nm) of the supernatant fluid was determined and results were expressed as 50%0 lysis.
Appropriate controls and complete blanks were run simultaneously.
RESULTS
Determination ofopsonic requirements. The opsonic requirements ofpneumococ-
cal types 6, 7, 18, and 23 were investigated by incubating bacteria in dilutions of
normal and MgEGTA chelated serum and comparing kinetics of neutrophil phago-
cytosis of the opsonized bacteria. The opsonic requirements of these serotypes are
summarized in Table 1L All four types were opsonized equally well in normal and
chelated serum at the 90% and 40% serum concentrations. Types 6 and 23 were also
opsonized equally well in normal and chelated 20% serum. Types 7 and 18 were
opsonized less effectively in concentrations ofchelated serum less than40%, although
type 18 was opsonized more efficiently than the other three types in 10% and 5%
chelated serum. Heat-stable factors provided negligible opsonic activity for Pn, 6, 7,
and 23, and slight activity for Pn 18. Therefore, these pneumococcal strains require
complement for optimal opsonization and utilize the alternative complement path-
way.
S. typhimurium was effectively opsonized in normal, MgEGTA chelated and C2
deficient serum as illustrated in Table 2. There was equal opsonicactivity in 20% and
10% chelated and normal serum, while 5% and 2.5% chelated serum provided less
opsonic activity. C2 deficient serum provided less opsonicactivity thaneithernormal
or chelated serum. However, at 5% and 2.5% concentrations the opsoniccapacities of
chelated and C2 deficient serum were similar. Therefore, this strain of S. typhimur-
ium is effectively opsonized via the alternative complement pathway.
Effect of whole pneumococci on serum hemolytic C3.9 activity and opsonic
capacity. Whole, viable S. pneumoniae were suspended to a concentration of 5 x
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TABLE I
Opsonic Requirements of S. pneumoniae types 6, 7, 18, and 23
Percent phagocytosis in opsonin concentration of:
Serotype Opsonin 90%o 40o 20o 10%o 5% A1I0o
NPS 76 72 78 39 15 2
6 MgEGTA/NPS 72 59 60 3* 3*
7 NPS 92 82 85 59 15 2
MgEGTA/NPS 84 79 13* 6* 5*
18 NPS 73 80 67 40 28 11
MgEGTA/NPS 74 72 36* 22* 11
23 NPS 78 75 77 48 24 5
MgEGTA/NPS 76 70 63 6* 4*
*P< .05
108/ml in normal and C2 deficient serum. The mixtures were incubated at 370C for
60 min, and aliquots of serum were withdrawn at 0 and 60 min; organisms were
removed by centrifugation, and the serum was frozen at -70°C for hemolytic C3-9
titrations. All four pneumococcal types decomplemented normal serum; hemolytic
C39 activity was reduced to 28% to 53% of the time 0 titer in the single experiment
illustrated by Table 3. Pn 6 was somewhat more active, and Pn 23 was least activein
effecting serum hemolytic complement activity.
To demonstrate the effect whole pneumococci might have on serum opsonic
capacity, pneumococci were separated by centrifugation (1600 g x 15 min), and the
serum was assayed for opsonic activity with salmonella. All four pneumococcal types
reduced the opsonic capacity of normal serum (Fig. 1). There was reduction in both
the initial rate of phagocytosis and in the maximal number of salmonella phagocy-
tized. There was a greater reduction of serum opsonic capacity after incubation with
Pn 18 than with Pn 6, 7, or 23 (Table4). Differences between percent phagocytosis in
serum preincubated with saline and with whole pneumococci were all significant at a
level of P< .05. It was also demonstrated in a single experiment that Pn 7 and Pn 18
reduced the opsonic capacity of C2 deficient serum for salmonella (Table 5). While
Pn 18 reduced opsonic capacity to the same extent inC2 deficient and normal serum,
Pn 7 reduced opsonic capacity to a slightly greater extent in normal serum suggesting
enhancement of the Pn 7 inhibition by the classical complement pathway.
No free PCP could be detected in the supernatant of the washed pneumococcal
suspensions measured by counterimmunoelectrophoresis, which in our laboratory
detects as little as 0.15,ug/ml of polysaccharide using a standard assay [18]. This
TABLE 2
Opsonic Requirements of Salmonella typhimurium
Percent phagocytosis in opsonin concentration of:
Opsonin 20o 10%o 5% 2.5%
NPS 69 64 61 41
MgEGTA/NPS 69 45 22t 1St
C2 def 56* 22* 16 11
*P < .05
tP< .005
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TABLE -3
Effect of Whole Pneumococci and Capsular Polysaccharide on the Hemolytic C3-9 Activity of Normal Serum
Percentage of initial serum C3 9 titer after incubation of normal serum with:
PCP (jug/ml)
Whole
Serotype Pn 100 50 10
6 28% 73% 57% 67%
7 38 66 53 69
18 33 64 63 61
23 53 78 97 56
Saline incubation with serum reduced the C 34 titer by 2%.
finding suggests that the complement activating properties of whole pneumococci
were not due to soluble polysaccharide in these experiments.
Effect of PCP on serum hemolytic C.3-9 activity and opsonic capacity. Purified
PCP of each serotypewas suspended in normal and C2 deficient serum. The mixtures
were incubated at 370C for 60 min and aliquots ofserum were withdrawn at 0 and 60
min and immediately frozen at -70°C forhemolyticC3.9titrations. Concentrations of
polysaccharide between 10 and 100Ag/ml reduced the hemolytic C 3 titer ofnormal
serum in the single experiment illustrated by Table 3. Serum C 39 activity was
reduced to 53% to 73% oftime 0 by polysaccharide oftypes 6, 7, and 18. Thesethree
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FIG. 1. Effect ofwholepneumococci(Pn) on serumopsonic capacity. Serum opsoniccapacitywasdirectly related to
the percent phagocytosis of salmonella using normal serum preincubated for 60 min with types 6, 7, 18, and 23
pneumococci, and serum preincubated with an equal volume of saline. Following preincubation, serum was diluted to
2.5% and used as an opsonin for salmonella. Opsonized salmonella were incubated with leukocytes, and percent
phagocytosis wasdetermined at 15 and 30 min. Each value represents the mean offourexperiments. Significance ofthese
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TABLE 4
Effect of Whole Pneumococci and Capsular Polysaccharide on the
Opsonic Capacity of Normal Serum for Salmonella
Percentage of initial serum opsonic capacity after
incubation of normal serum with:
PCP (Lg/ml)
Whole
Serotype Pn 100 50 10 5 1
6 70%* 78%t 72%t 76%t 76% 72%
7 74# 73 45t 62t 68 85
18 59t 75t 75# 71t 76 72
23 76t 85T 87* 67t 79 74
*P< .05
#P< .025
tP< .005
types were equally effective in decomplementing serum at high and low concentra-
tions of PCP. Type 23 polysaccharide was most effective in the lowest concentration
and had minimal activity at 50 I&g/ml.
To demonstrate the effect capsular polysaccharide alone might have on serum
opsonic capacity, 50Aug/ml concentrations of each polysaccharide were incubated
with serum, and the serum was assayed for opsonic capacity with salmonella.
Polysaccharide of types 6, 7, and 18 partially inhibited serum opsonization while
PCP 23 had little effect (Fig. 2). Lower concentrations of PCP were also tested for
their effect on serum. Polysaccharide concentrations of types 6 and 18 as low as 1
,ug/ml were as active as l0,g/ ml inreducing serum opsoniccapacity(Table4). Type
7 polysaccharide showed optimum activity at a concentratin of 50,g/ml, while type
23 polysaccharide produced the greatest inhibition when used in lower concentra-
tions. Reduction of serum opsonic capacity was directly related to the degree of
serum decomplementation produced by each PCP (Tables 3 and 4). Polysaccharide
of types 7 and 18 also reduced the serum opsonic capacity of C2 deficient serum for
salmonella in a single experiment (Table 5). As with the whole organisms, type 7
polysaccharide reduced the opsonic capacity of normal serum to a slightly greater
extent than of C2 deficient serum, while PCP 18 was equally active in both sera.
To further characterize the effect of capsular polysaccharide on pneumococcal
opsonic capacity, serum was preincubated with each of two polysaccharides (PCP 7
and 23) and opsonic capacity for the homologous pneumococcal type was deter-
mined. Table 6 illustrates the results of a representative experiment. Type 7
TABLE 5
Effect of Whole Pneumococci and Capsular Polysaccharide on the
Opsonic Capacity of C2 Deficient Serum for Salmonella
Percentage of initial serum opsonic capacity after
incubation of C2 deficient serum with:
Whole PCP (jg/ml)
Serotype Pn 50
7 85% 52%
18 58 73GIEBINK ET AL.
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FIG. 2. Effect of pneumococcal capsular polysaccharide (PCP) on serum opsonic capacity. Serum opsonic capacity
was directly related to the percent phagocytosis ofsalmonella using normal serum preincubated for 60 min with 50p.g/ml
polysaccharide from types 6, 7, 18, and 23 pneumococci, and serum preincubated with an equal volume of saline.
Following preincubation, serum was diluted to 2.5% and used as an opsonin for salmonella. Opsonized salmonella were
incubated with leukocytes, and percent phagocytosis was determined at 15 and 30 min. Each value represents the mean of
four experiments. Significance of these differences are shown in Table 4.
polysaccharide at concentrations as low as 5 Ag/ml produced a striking reduction in
serum opsonic capacity for type 7 pneumococci. Type 23 polysaccharide concentra-
tions as low as I jg/ml produced a marked reduction in serum opsonic capacity for
type 23 pneumococci.
DISCUSSION
Streptococcus pneumoniae is a clinically significant pathogen. Although antibiot-
ics have reduced mortality, the case-fatality rate for bacteremic pneumococcal
pneumonia has remained between 20% and 30% over the past decade [19,20]. The
frequency of pneumococcal disease has also not changed appreciably. Nielsen
reported in 1945 that the majority (48%) of bacteria isolated from the middle ears of
children with acute otitis media were S. pneumoniae[21]. Three decades later, Howie
found a similar frequency of pneumococcal isolates (35%) from children with this
condition, and also observed that first episodes of pneumococcal otitis media during
infancy predispose children to recurrent acute otitis media [22,23]. S. pneumoniae is
also the most frequent cause of occult bacteremia in febrile children and in patients
with post-splenectomy sepsis [24,25].
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TABLE 6
Effect of Capsular Polysaccharide on the Opsonic Capacity of Normal Serum
for the Homologous Pneumococcal Serotype
Percentage of initial serum opsonic capacity after
incubation of normal serum with:
PCPQ.Ug/ml)
Serotype 50 10 5 1
7 23% 26% 32% 72%
23 43 37 43 54
Eighty-three distinct pneumococcal serotypes have been described, but only a few
types are commonly encountered in patients with pneumococcal infection. These
types have remained remarkably constant over the past decade: the majority
(78-84%) of isolates from patients with pneumococcal bacteremia, meningitis, and
otitis media are types 1, 3, 4, 6, 7, 8, 9, 12, 14, 18, 19, and 23 [19,26,27]. Why certain
serotypes predominate and how S. pneumoniae injures the host are questions that
remain unanswered. Fine observed that pneumococcal serotypes varyintheirspecific
opsonic requirements and described three patterns of pneumococcal opsonization
[7]. Several types (7, 12, 14, and 25) decomplemented serum by activating the
alternative pathway of complement in the absence of specific antibody, other types
(3, 4, and 8) reduced C3 levels bytheinteraction ofantibody with alternative pathway
components and type 1 did not activate C3 via the alternative pathway even in the
presence ofspecific antibody. Thesedifferences incomplement fixingabilitymaygive
selective advantages to certain serotypes for host invasion and injury. Patients
lacking critical pneumococcal opsonins, either because of primary deficiency or
secondary to acute infection, may be unable to phagocytize and kill these microbes.
Dorff, Coonrod, and Rytel, using a rapid immunoprecipitin method, counterim-
munoelectrophoresis, have detected from 0.1 to 64, g/ml of PCP in the serum of
patients with bacteremia, meningitis, and pneumonia due to types 1, 3, 4, 6, 7, 9, 12,
15, 22, 23, and 34 [1,2,3,4,18,28]. They noted a progressive decline in the level of
serum PCP after initiation of therapy but antigenemia persisted for longer than one
month in 5 of 19 patients[1]. Others have speculated that PCP might be a subcellular
virulence factor causing host injury. Pillemer et al. demonstrated that large amounts
(3,000 Mg) of types 4 and 14 PCP decomplemented human serum by removal or
inactivation of properdin [29]. More recently, PCP of types 1, 4, and 25 in
concentrations as low as 10 Ig/ml has been shown to reduce C3 levels inC4 deficient
guinea pig serum, while PCP of types 2, 3, 14, and 19 did not [10]. Others have
observed patients with severe pneumococcal disease due to a variety of serotypes,
including types 3, 4, and 19, withlow levels offactor B ofthealternative pathway and
normal levels of two early components (Clq, C4) of the classical pathway [30].
Coonrod and Rylko-Bauer demonstrated that the functional activity ofthe alterna-
tive pathway was markedly depressed during the acute phase of pneumococcal
pneumonia, especially in those patients with bacteremia [31]. Thus, we considered
that patients with pneumococcal infection and antigenemia may have an acquired
alternative pathway defect affecting opsonization of pneumococci.
The pneumococcal serotypes selected for this investigation were all opsonized via
the alternative pathway and included both lower and higher numbered types
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18 was more efficient, most likely due to higher levels of type 18 pneumococcal
antibody in the serum pool employed. The opsonic requirements of types 6, 18, and
23 have been more completely defined in a separate report[5]. It is important to note
that our observations relate only to these single strains, and that different strains ofa
given serotype may vary in their ability to activate complement.
Serum incubated with suspensions of whole, viable S. pneumoniae and with
purified PCP from each type had reduced biologic activity of C3 measured by the
hemolytic C3-9 assay and by opsonic capacity for Salmonella typhimurium. Opsoni-
zation of salmonella was selected as a measure of serum opsonic capacity since the
organism is opsonized effectively and independently of type-specific pneumococcal
antibody via the alternative pathway. Suspensions of whole S. pneumoniae showed
considerably greater activity than the homologous PCP in reducing hemolytic C3-9
activity. While the quantity of PCP contained in the whole cell preparations was not
measured, others have shown for types 1 and 2 S. pneumoniae that 5 x 108 bacteria
yielded 1.5 and 2.0Ag of polysaccharide, respectively [32]. This finding suggests that
PCP might not be the most active subcellular factor in reducing levels of comple-
ment. However, the same suspensions ofwholetypes 6, 7, and 23 S. pneumoniaewere
no more active than the highest concentrations ofthe homologous PCP in reducing
serum opsonic capacity. Whole type 18S.pneumoniae were slightly more activethan
type 18 PCP. It is possiblethat PCP aggregated on the surface ofthis strain was more
active or that there was simply more PCP in that particular whole cell preparation.
We were unable to explain the different results, confirmed in repeated experiments,
using the two assays. While these assays measured different endpoints along the
complement cascade, the measurement of opsonic capacity would more closely
reflect changes in the functional process of opsonization.
Capsular polysaccharide in concentrations as low as 1 &g/ml significantly reduced
the serum opsonic capacity. For at least two types (6 and 18), maximum opsonic
inhibition was present at the lowest concentration of PCP studied, and inhibition
produced by PCP 7 and 23 was maximal in the mid-range of PCP concentration
used. Repeated experiments confirmed the greater activity of PCP 7 and 23 in this
mid-range. Suspensions of whole S. pneumoniae and PCP of types 7 and 18 also
reduced the opsonic capacity of C2 deficient serum, providing additional evidence
that these polysaccharides primarily activated C3 via the alternative pathway.
The effect of PCP on serum opsonic activity for the homologous pneumococcus
was greater than its effect on salmonella opsonization. The greater inhibition of
pneumococcal opsonization may have been due to binding oftype-specific antibody
by PCP. We have shown in previous experiments that antibody enhances pneumo-
coccal opsonization in the presence of complement [5]. Some patients with bacter-
emic pneumococcal disease show absent or reduced type-specific antibody produc-
tion associated with high serum levels of PCP [3]. We observed that bacteremic
patients with PCP antigenemia have reduced serum complement levels and reduced
pneumococcal opsonic activity [33]. Testing these patient sera with the salmonella
opsonic assay showed that the opsonic defect effected the alternative pathway.
Opsonic activity and serum complement increased during convalescence with the
disappearance of PCP antigen. These in vivo observations support the in vitro
experiments with PCP antigen.
Thus, PCP antigen can activate complement and reduce serum opsonic activity.
An alternative pathway opsonic defect might be expected to have its greatest impact
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on host defenses during the early phase of infection, prior to the development of
specific antibody required for utilization of the more efficient classical pathway for
opsonization. However, PCP may not be unique inits ability to activate complement
since purified pneumococcal cell wall also activates the alternative pathway [34] and
inhibits neutrophil phagocytosis [35]. Pneumococcal M protein [36] and C polysac-
charide [37] may also activate complement since these elements may in part
determine opsonic requirements. It is possible that several or all ofthese subcellular
elements accounted for the greater effect of whole pneumococci compared with PCP
on hemolytic complement activity in our experiments. The association of increased
PCP levels and increased mortality in bacteremic patients [3] may simply reflect a
greater concentration of invading bacteriaand, as such, a greater concentration ofall
the subcellular elements including PCP. To define the relative activities of these
elements on inhibition of alternative pathway opsonization, studies are required to
compare cell wall, cell membrane, capsular polysaccharide, and whole cell prepara-
tions from several strains and serotypes of S. pneumoniae in human serum.
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